Bayer Schering Pharma has described a tentative decision by UK health technology assessors not to recommend its Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) as a major blow for patients in the national health service in England and Wales.
The National Institute for health and Clinical Excellence (NICE) has circulated draft guidance rejecting sorafenib for HCC patients with Barcelona clinic liver cancer stage C disease in whom surgical or...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?